ADHD Pill Faces High Hurdle in Europe as Stigma Persists

The European debut of a pill to treat children with attention deficit hyperactivity disorder faces a major hurdle: convincing people the condition exists.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.